Advanced search
1 file | 1.04 MB Add to list

Myotonic dystrophy type 1 as a major risk factor for severe COVID-19?

Sebastiaan Dhont (UGent) , Rutger Callens, Dieter Stevens (UGent) , Fré Bauters (UGent) , Jan De Bleecker (UGent) , Eric Derom (UGent) and Eva Van Braeckel (UGent)
Author
Organization
Abstract
The coronavirus disease 2019 (COVID-19) pandemic is challenging health care systems worldwide. People with myotonic dystrophy type 1 (DM1) represent a high-risk population during infectious disease outbreaks, little is known about the potential impact of COVID-19 on patients with DM1. We studied the clinical course of COVID-19 in three hospitalized patients with myotonic dystrophy type 1 or Steinert's disease, between April 1, 2020-April 30-2020. All three had advanced Steinert's disease receiving non-invasive nocturnal home ventilatory support. Two of them lived in a residential care centre. Two patients had a limited respiratory capacity, whereas one patient had a rather preserved functional capacity but more comorbidities. Two out of three patients were obese, none of them had diabetes mellitus. Two patients received hydroxychloroquine. Despite maximal supportive care with oxygen therapy, antibiotics, intensive respiratory physiotherapy and non-invasive positive pressure ventilation, all three patients eventually died due to COVID-19. Our case series of three patients with DM1 admitted for COVID-19 confirms that they are at high risk for severe disease and poor outcome. Clinical trials are needed to define best practices and determinants of outcomes in this unique population.
Keywords
FLOW, Steinert's disease, Myotonic dystrophy, Neuromuscular disorders, COVID-19, SARS-CoV-2

Downloads

  • (...).pdf
    • full text (Published version)
    • |
    • UGent only
    • |
    • PDF
    • |
    • 1.04 MB

Citation

Please use this url to cite or link to this publication:

MLA
Dhont, Sebastiaan, et al. “Myotonic Dystrophy Type 1 as a Major Risk Factor for Severe COVID-19?” ACTA NEUROLOGICA BELGICA, Springer, 2021, doi:10.1007/s13760-020-01514-z.
APA
Dhont, S., Callens, R., Stevens, D., Bauters, F., De Bleecker, J., Derom, E., & Van Braeckel, E. (2021). Myotonic dystrophy type 1 as a major risk factor for severe COVID-19? ACTA NEUROLOGICA BELGICA. https://doi.org/10.1007/s13760-020-01514-z
Chicago author-date
Dhont, Sebastiaan, Rutger Callens, Dieter Stevens, Fré Bauters, Jan De Bleecker, Eric Derom, and Eva Van Braeckel. 2021. “Myotonic Dystrophy Type 1 as a Major Risk Factor for Severe COVID-19?” ACTA NEUROLOGICA BELGICA. https://doi.org/10.1007/s13760-020-01514-z.
Chicago author-date (all authors)
Dhont, Sebastiaan, Rutger Callens, Dieter Stevens, Fré Bauters, Jan De Bleecker, Eric Derom, and Eva Van Braeckel. 2021. “Myotonic Dystrophy Type 1 as a Major Risk Factor for Severe COVID-19?” ACTA NEUROLOGICA BELGICA. doi:10.1007/s13760-020-01514-z.
Vancouver
1.
Dhont S, Callens R, Stevens D, Bauters F, De Bleecker J, Derom E, et al. Myotonic dystrophy type 1 as a major risk factor for severe COVID-19? ACTA NEUROLOGICA BELGICA. 2021;
IEEE
[1]
S. Dhont et al., “Myotonic dystrophy type 1 as a major risk factor for severe COVID-19?,” ACTA NEUROLOGICA BELGICA, 2021.
@article{8689683,
  abstract     = {{The coronavirus disease 2019 (COVID-19) pandemic is challenging health care systems worldwide. People with myotonic dystrophy type 1 (DM1) represent a high-risk population during infectious disease outbreaks, little is known about the potential impact of COVID-19 on patients with DM1. We studied the clinical course of COVID-19 in three hospitalized patients with myotonic dystrophy type 1 or Steinert's disease, between April 1, 2020-April 30-2020. All three had advanced Steinert's disease receiving non-invasive nocturnal home ventilatory support. Two of them lived in a residential care centre. Two patients had a limited respiratory capacity, whereas one patient had a rather preserved functional capacity but more comorbidities. Two out of three patients were obese, none of them had diabetes mellitus. Two patients received hydroxychloroquine. Despite maximal supportive care with oxygen therapy, antibiotics, intensive respiratory physiotherapy and non-invasive positive pressure ventilation, all three patients eventually died due to COVID-19. Our case series of three patients with DM1 admitted for COVID-19 confirms that they are at high risk for severe disease and poor outcome. Clinical trials are needed to define best practices and determinants of outcomes in this unique population.}},
  author       = {{Dhont, Sebastiaan and Callens, Rutger and Stevens, Dieter and Bauters, Fré and De Bleecker, Jan and Derom, Eric and Van Braeckel, Eva}},
  issn         = {{0300-9009}},
  journal      = {{ACTA NEUROLOGICA BELGICA}},
  keywords     = {{FLOW,Steinert's disease,Myotonic dystrophy,Neuromuscular disorders,COVID-19,SARS-CoV-2}},
  language     = {{eng}},
  pages        = {{5}},
  publisher    = {{Springer}},
  title        = {{Myotonic dystrophy type 1 as a major risk factor for severe COVID-19?}},
  url          = {{http://dx.doi.org/10.1007/s13760-020-01514-z}},
  year         = {{2021}},
}

Altmetric
View in Altmetric
Web of Science
Times cited: